Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-six analysts that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $152.4167.

Several equities analysts have commented on GILD shares. Mizuho boosted their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Cantor Fitzgerald upped their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a report on Wednesday. Needham & Company LLC increased their price target on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a research report on Wednesday. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. Finally, TD Cowen raised their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $151.81 on Friday. The company has a market cap of $188.35 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 0.81 and a beta of 0.36. The stock’s 50 day simple moving average is $129.59 and its 200-day simple moving average is $121.98. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the prior year, the business earned $1.90 earnings per share. The business’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares of the company’s stock, valued at $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 319,391 shares of company stock valued at $44,141,101. 0.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the company. Csenge Advisory Group grew its stake in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares in the last quarter. Railway Pension Investments Ltd lifted its holdings in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after buying an additional 42,200 shares during the last quarter. TriaGen Wealth Management LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $1,274,000. iA Global Asset Management Inc. raised its position in shares of Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after acquiring an additional 23,046 shares in the last quarter. Finally, Sector Gamma AS raised its position in shares of Gilead Sciences by 15.9% during the 3rd quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after acquiring an additional 20,239 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.